Effect of First-Line Ziconotide Intrathecal Drug Therapy for Neuropathic Pain on Disability, Emotional Well-Being, and Pain Catastrophizing

Authors:

Abstract
No abstract available
Funding Information
  • Medtronic
  • Boston Scientific Corporation
  • National Institutes of Health (2R01CA166379-06, U44NS115111)
  • Abbott Fund

This publication has 34 references indexed in Scilit: